The cancer immunity cycle involves several sequential steps leading to an effective T cell-mediated tumor eradication. However, many steps in the cycle can be disrupted, resulting in a tumor evading the host’s immune surveillance and response.

Understanding the cancer immunity cycle as a whole and mechanisms at each step is important for developing immunotherapeutics with a more durable response.

In this webinar, Dr Nataliia Beztsinna and Dr. Marten Hornsveld describe the role of tumor microenvironment (TME) compartments in clinical responses, as well as ex vivo patient-derived tissue technologies capable of maintaining the native TME for pre-clinical testing.

Complex in vitro models with the use of human stromal and immune co-cultures are discussed, together with the advantages of HCI to quantify intact tumor biology.